PCN37 - Management of Soft Tissue Sarcoma in France - A Retrospective Analysis of The French Clinical Biological Sarcoma Database (CONTICANET)

Abstract

The primary endpoint is to define the percentage of advanced soft tissue sarcoma (STS) patients benefiting from a first line of chemotherapy. The secondary endpoints aimed to describe the epidemiological characteristics, anatomopathological investigation, diagnostic procedures as well as therapeutic strategy for the management of patients, with STS in France. This observational, retrospective and national study is based on the patient databases of the European CONTICANET "CONnective TIssue Cancer NETwork" network. This database contains anonymised information describing the tumour, treatment and follow-up as well as tumour sample availability and molecular biology analyses for mesenchymal tumours except GIST and bone tumours. 1 099 patients with advanced STS and diagnosed between 2012 and 2013 were selected and existing data analysed. The primary endpoint showed that within a subset of 745 patients from three centers, first line chemotherapy was given 67.4% of patients with advanced STS, 71.4% of patients with metastasis at diagnosis and 70.0% of patients with appearance of metastasis. Then among secondary endpoints, patients were as follows : mean of 59.28 years at diagnosis; 52.1% female; 78.8% of histotypes were either undifferentiated sarcoma, lieomyosarcoma, miscellaneous sarcomas or liposarcoma; 74.4% tumour sites were either limb, internal trunk, trunk wall; in 83.8% of cases tumour was deep; and 12.5% of patients had locally advanced of metastatic STS at diagnosis. This pharmacoepidemiological study shows how useful high-quality medical databases are to study rare diseases and their management in real life. This study, carried out as part of a public/private partnership, showed that the majority of patients with STS are treated with first line chemotherapy.